Ascendis Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
12.09B
Market cap12.09B
Price-Earnings ratio
-40.49
Price-Earnings ratio-40.49
Dividend yield
Dividend yield
Average volume
362.85K
Average volume362.85K
High today
$205.00
High today$205.00
Low today
$178.00
Low today$178.00
Open price
$200.37
Open price$200.37
Volume
666.51K
Volume666.51K
52 Week high
$216.45
52 Week high$216.45
52 Week low
$118.03
52 Week low$118.03

Stock Snapshot

Ascendis Pharma(ASND) stock is priced at $186.13, giving the company a market capitalization of 12.09B. It carries a P/E multiple of -40.49.

During the trading session on 2025-11-12, Ascendis Pharma(ASND) shares reached a daily high of $205.00 and a low of $178.00. At a current price of $186.13, the stock is +4.6% higher than the low and still -9.2% under the high.

Trading activity shows a volume of 666.51K, compared to an average daily volume of 362.85K.

Over the past 52 weeks, Ascendis Pharma(ASND) stock has traded between a high of $216.45 and a low of $118.03.

Over the past 52 weeks, Ascendis Pharma(ASND) stock has traded between a high of $216.45 and a low of $118.03.

ASND News

TipRanks 3h
Ascendis Pharma Grants Warrants to Employees in Strategic Move

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...

TipRanks 4h
Ascendis Pharma reports Q3 EPS vs. last year

Reports Q3 revenue EUR 213.63M vs. EUR 57.83M last year. “With our achievements in the third quarter and year to date, Ascendis is making great progress toward...

TipRanks 5d
Ascendis Pharma announces new pooled analysis on TransCon PTH

Ascendis Pharma (ASND) announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function in adults with hypoparathy...

Analyst ratings

100%

of 16 ratings
Buy
100%
Hold
0%
Sell
0%
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.